Sanofi — 13F Holdings & Portfolio

CIK 1121404 · latest 13F-HR filed 2026-11-05

Sanofi manages $629.9M in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are MGTX (21.30%), INBX (18.40%), NVAX (11.81%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 6 new positions and exited 0; 4 existing positions rose in reported value and 6 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$629.9M

Long-equity book

Holdings
16

Distinct positions

Period
2026-09-30

Filed 2026-11-05

Q/Q Activity
+6 / −0 / ↑4 / ↓6

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 92.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 4 →

Top Trims

Show all 6 →

Exited Positions

  • No exits this quarter.
Show all 0 →

Sanofi Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 MeiraGTx Holdings plc MGTX G59665102 $134.2M 21.30% 12,197,737 SH
2 Inhibrx Biosciences, Inc. INBX 45720N103 $115.9M 18.40% 1,157,926 SH
3 Novavax NVAX 670002401 $74.4M 11.81% 6,880,481 SH
4 Korsana Biosciences KRSA 23255M303 $63.8M 10.13% 1,994,011 SH
5 Odyssey Therapeutics Inc. ODTX 67613T104 $44.2M 7.02% 1,990,200 SH
6 AnaptysBio ANAB 032724106 $41.3M 6.56% 821,917 SH
7 Agomab Therapeutics NV AGMB 00860C102 $30.9M 4.90% 2,783,096 SH
8 First Tracks Biotherapeutics Inc. TRAX 337185102 $29.1M 4.62% 821,917 SH
9 Electra Therapeutics Inc ETRA 284825106 $27.7M 4.40% 2,461,948 SH
10 Attovia Therapeutics Inc ATTO 04987L102 $18.6M 2.95% 1,082,855 SH
11 Latigo Biotherapeutics Inc LTGO 517954103 $11.2M 1.78% 672,778 SH
12 Immuneering Corp IMRX 45254E107 $11.1M 1.76% 2,708,559 SH
13 MapLight Therapeutics Inc. MPLT 56565P103 $9.3M 1.48% 912,041 SH
14 Scribe Therapeutics SCTX 811033109 $9.2M 1.46% 500,000 SH
15 SAB BIOTHERAPEUTICS INC SABS 78397T202 $7.0M 1.11% 2,198,500 SH
16 Q32 Bio Inc. QTTB 746964105 $2.0M 0.32% 244,083 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-05 $629.9M 16 0001193125-26-448717
2026-06-30 2026-07-28 $534.0M 10 0001193125-26-318812
2026-03-31 2026-05-07 $336.0M 9 0001193125-26-210525
2025-12-31 2026-02-11 $310.4M 8 0001193125-26-045633
Filer Information
Address
46 AVENUE DE LA GRANDE ARMEE
PARIS, I0 75017
Phone
33153774400
Filing Manager
Sanofi
Paris, I0
Signatory
Alexandra Roger
Head of Legal Corporate & Finance